Epistem’s Biomarker Focus in the US
Epistem’s biomarker collaborations in North America will focus on preclinical and clinical oncology drug development providing a means of translating drug effect in specific oncology pathways such as Hedgehog, WNT, Notch, Beta Catenin, PI3 kinase and androgen signalling as well as providing an ideal platform for evaluating therapies aimed at specific RNA targets. The Biomarker Laboratory services will be delivered within a regulatory framework to comply with Good Clinical Laboratory Practice (GcLP).
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.